Abstract：Objective To explore the clinical effect of Recombinant Human Interleukin-11 combined with Docetaxel and Carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 80 patients with advanced NSCLC admitted to Maanshan People′s Hospital, Anhui Province from December 2015 to June 2019 were selected and divided into the control group and the treatment group according to the random number table method, with 40 cases in each group. The control group were treated with Docetaxel and Carboplatin, while the treatment group were treated with Recombinant Human Interleukin-11 combined with Docetaxel and Carboplatin for 21 days as one chemotherapy cycle, and both groups were treated for 3 consecutive chemotherapy cycles. The clinical effect of two groups after treatment was evaluated and compared. Eastern cooperative oncology group (ECOG) scores, cytokeratin-19-fragment (CYFRA21-1), insulin-like growth factors-1 (IGF-1), squamous cell carcinoma antigen (SCC-Ag) and peripheral blood CD3+, CD4+, and CD8+ levels were compared between the two groups before and after treatment. The occurrence of toxic side effects during treatment was compared between the two groups. Results The total remission rate in the treatment group was significantly higher than that in the control group, with statistically significant difference (P ＜ 0.05). After treatment, ECOG scores of both groups were lower than those before treatment, and the treatment group was lower than the control group, with statistically significant differences (all P ＜ 0.05). After treatment, serum CYFRA21-1, IGF-1 and SCC-Ag levels in the two groups were all lower than those before treatment, and the treatment group was lower than the control group, with statistically significant differences (all P ＜ 0.05). After treatment, the levels of CD3+ and CD4+ in the control group were lower than those before treatment, and the levels of CD8+ were higher than those before treatment. The levels of CD3+ and CD4+ in the treatment group were higher than those before treatment, and the levels of CD8+ were lower than those before treatment. The levels of CD3+ and CD4+ in the treatment group were higher than those in the control group, and the levels of CD8+ were lower than those in the control group, with statistically significant differences (all P ＜ 0.05). During the treatment, the incidence of toxic side effects in the treatment group was lower than that in the control group, and the difference was statistically significant (P ＜ 0.05). Conclusion Recombinant Human Interleukin-11 combined with Docetaxel and Carboplatin has a significant clinical effect in the treatment of advanced NSCLC, which can improve the physical strength and quality of life of patients, down-regulate the serum CYFRA21-1, IGF-1 and SCC-Ag levels, and improve the immune function of the body.
高尔云 崔方博 李敏. 重组人白细胞介素-11联合多西紫杉醇、卡铂治疗晚期非小细胞肺癌的效果[J]. 中国医药导报, 2020, 17(20): 118-122.
GAO Eryun CUI Fangbo LI Min. Effect of Recombinant Human Interleukin-11 combined with Docetaxel and Carboplatin in the treatment of advanced non-small cell lung cancer. 中国医药导报, 2020, 17(20): 118-122.
2020, Vol. 17 
京公网安备 11010502046598号